Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg |
ln Vitro |
Quinacrine (5-20 μM; 24 hours) inhibits the development of SGC-7901 cells [1]. Quinacrine (7.5 and 15 μM; 24 hours) promotes apoptosis in SGC-7901 cells, which is connected with mitochondria-dependent signaling pathways including p53 overexpression and caspase-3 activation pathways [1]. Treatment with quinacrine (15 μM; 24 h) greatly boosted the levels of pro-apoptotic proteins, including cytochrome c, Bax, and p53, and lowered the levels of the anti-apoptotic protein Bcl-2, consequently boosting Bax/Bcl-2 The ratio is conducive to cell apoptosis[1].
|
---|---|
ln Vivo |
Quinacrine (100 mg/kg, three times a week for two weeks) prolonged the median survival time (MST) and markedly reduced circulating blasts on days 30 and 31. Quinacrine did not cause treated animals' body weight to decrease at the tested levels [2].
|
Cell Assay |
Cell Viability Assay [1]
Cell Types: SGC-7901 Cell Tested Concentrations: 0, 5, 10, 15 and 20 μM Incubation Duration: 24 hrs (hours) Experimental Results: Cell viability was inhibited in a dose-dependent manner with an average IC50 value of 16.18 μM. Apoptosis analysis [1] Cell Types: SGC-7901 Cell Tested Concentrations: 7.5 and 15 μM Incubation Duration: 24 hrs (hours) Experimental Results: Compared with the control group, the percentage of apoptotic cells (including early and late apoptosis) increased to 26.30%. 3.37%. Western Blot Analysis [1] Cell Types: SGC-7901 Cell Tested Concentrations: 15 μM Incubation Duration: 24 hrs (hours) Experimental Results: The relative amount of cytochrome c protein was increased from 0.10 to 0.24. The relative amount of p53 protein increased Dramatically, from 0.06 to 0.19. The Bax/Bcl-2 ratio increased sharply from 1.21 to 2.59. |
Animal Protocol |
Animal/Disease Models: Acute myeloid leukemia (AML) female SCID mouse-PS model [2]
Doses: 100 mg/kg Route of Administration: po (oral gavage); 3 times a week for two consecutive weeks Experimental Results: On the first In an in vivo mouse study of AML, evaluation of circulating leukemia cells (expressed as a percentage of white blood cells (WBC)) detected in blood samples at day 30/31 demonstrated that 72% were human tumor cells in control mice, whereas In mice treated with quinacrine, the rate was only 2.2%. The MST of control mice was 34 days, while the MST of quinacrine-treated mice was 46 days. |
References |
[1]. Xiaoyang Wu, et al. Quinacrine Inhibits Cell Growth and Induces Apoptosis in Human Gastric Cancer Cell Line SGC-7901. Curr Ther Res Clin Exp. 2012 Feb;73(1-2):52-64.
[2]. Anna Eriksson, et al. Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects. Leuk Res. 2017 Dec;63:41-46. |
Molecular Formula |
C23H30N3OCL.HCL
|
---|---|
Molecular Weight |
436.41774
|
CAS # |
6151-30-0
|
Related CAS # |
Quinacrine dihydrochloride;69-05-6;l-Atabrine dihydrochloride;56100-42-6;d-Atabrine dihydrochloride;56100-41-5;Quinacrine;83-89-6
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
CCN(CC)CCCC(C)N=C1C2=C(C=C(C=C2)Cl)NC3=C1C=C(C=C3)OC.Cl.Cl.O.O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2914 mL | 11.4569 mL | 22.9137 mL | |
5 mM | 0.4583 mL | 2.2914 mL | 4.5827 mL | |
10 mM | 0.2291 mL | 1.1457 mL | 2.2914 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.